Quantification of Translocator Protein (18 kDa) in the Human Brain with PET and a Novel Radioligand, 18F-PBR06
Authors:
- 12 June 2009
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 50 (7) , 1047-1053
Abstract
Translocator protein (TSPO) (18 kDa), formerly called the peripheral benzodiazepine receptor, is upregulated on activated microglia and macrophages and is, thus, a biomarker of inflammation. We previously reported that an 11C-labeled aryloxyanilide (half-life, 20 min) was able to quantify TSPOs in the healthy human brain. Because many PET centers would benefit from a longer-lived 18F-labeled radioligand (half-life, 110 min), the objective of this study was to evaluate the ability of a closely related aryloxyanilide (18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline [18F-PBR06]) to quantify TSPOs in the healthy human brain. Methods: A total of 9 human subjects were injected with 18F-PBR06 (∼185 MBq) and scanned for 5 h, with rest periods outside the camera. The concentrations of 18F-PBR06, separated from radiometabolites, were measured in arterial plasma. Results: Modeling of regional brain and plasma data showed that a 2-tissue-compartment model was superior to a 1-tissue-compartment model. Even if data for all time points were used for the fitting, concentrations of brain activity measured with PET were consistently greater than the modeled values at late (280–300 min) but not at early time points. The greater values may have been caused by the slow accumulation of radiometabolites in the brain. To determine an adequate time for more accurate measurement of distribution volume (VT), which is the summation of receptor binding and nondisplaceable activity, we investigated which scan duration would be associated with maximal or near-maximal identifiability. We found that a scan of 120 min provided the best identifiability of VT (∼2%). The images showed no significant defluorination. Conclusion: 18F-PBR06 can quantify TSPOs in the healthy human brain using 120 min of image acquisition and concurrent measurements of radioligand in plasma. Although brain activity is likely contaminated with radiometabolites, the percentage contamination is thought to be small (18F-PBR06 is a longer-lived and promising alternative to 11C-labeled radioligands to measure TSPOs as a biomarker of inflammation in the brain.Keywords
This publication has 27 references indexed in Scilit:
- Single-Step High-Yield Radiosynthesis and Evaluation of a Sensitive18F-Labeled Ligand for Imaging Brain Peripheral Benzodiazepine Receptors with PETJournal of Medicinal Chemistry, 2009
- Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptorsNuclear Medicine and Biology, 2008
- Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammationNeuroImage, 2008
- Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptorsNeuroImage, 2008
- A comparison of the high‐affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)‐PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activationJournal of Neurochemistry, 2007
- The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: From pathology to imagingProgress in Neurobiology, 2006
- Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 1993
- Evidence for species differences in ‘peripheral’ benzodiazepine receptors: An autoradiographic studyNeuroscience Letters, 1986
- ‘Peripheral’ benzodiazepine binding sites in human brain and kidney: Autoradiographic studiesNeuroscience Letters, 1986
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974